The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
作者： Marcellus Simadibrata , Murdani Abdullah , Ari Fahrial Syam , Achmad Fauzi , Abdul Aziz Rani
DOI:
关键词: Pyruvate kinase 、 Adenoma 、 Oncology 、 Gastroenterology 、 Inflammatory bowel disease 、 Histology 、 Colorectal cancer 、 Medicine 、 Tumor M2-PK 、 Colonoscopy 、 Feces 、 Internal medicine
摘要: AIM to evaluate the performance of fecal tumor M2 pyruvate kinase (M2PK) as a diagnostic biomarker for colorectal cancer (CRC) screening in high-risk or symptomatic populations. METHODS consecutive patients (N=328) who were referred elective colonoscopy prospectively enrolled. One walnut-sized stool sample was collected from each patient analysis M2PK content using an ELISA kit. No dietary restrictions applied. The clinical pathologists conducted analyses blinded patients' confirmed diagnoses. Levels compared with histopathological results biopsies. RESULTS 328 underwent examinations, 197 (60.1%) men and 131 (39.9%) women. Based on examination, 83 (25.3%) had normal bowel histology, 42 (12.8%) CRC, 67 (20.4%) adenoma, 19 (5.8%) inflammatory disease, three (0.9%) amoebic colitis, 114 (34.8%) infective colitis. cutoff level concentration defined 4.00 U/mL. sensitivity, specificity, positive predictive value, negative value test 71.4%, 71.0%, 73.5%, 94.4%, respectively. There significant association between CRC (P<0.001). detected 16 tumors among (23.9%) cases eight (42.1%) 35 (30.7%) two (66.7%) CONCLUSION has good sensitivity specificity detection, especially
inaactamedica.org 参考文章(31)
Ngoumou Bk, Hardt Pd, Rupp J, Schnell-Kretschmer H, Kloer Hu, Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Research. ,vol. 20, pp. 4965- 4968 ,(2000)
Basil Morson, President's address. The polyp-cancer sequence in the large bowel. Journal of the Royal Society of Medicine. ,vol. 67, pp. 451- 457 ,(1974) , 10.1177/00359157740676P115
Toepler M, Ngoumou B, Hardt Pd, Rupp J, Kloer Hu, Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Research. ,vol. 23, pp. 851- 853 ,(2003)
Carolin Tonus, Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK World Journal of Gastroenterology. ,vol. 12, pp. 7007- 7011 ,(2006) , 10.3748/WJG.V12.I43.7007
Bo Zhang, Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls World Journal of Gastroenterology. ,vol. 10, pp. 1643- 1646 ,(2004) , 10.3748/WJG.V10.I11.1643
David A Lieberman, William V Harford, Dennis J Ahnen, Dawn Provenzale, Stephen J Sontag, Thomas G Schnell, Gregorio Chejfec, Donald R Campbell, Theodore E Durbin, John H Bond, Douglas B Nelson, Stephen L Ewing, George Triadafilopoulos, Francisco C Ramirez, John G Lee, Judith F Collins, M Brian Fennerty, Tiina K Johnston, Christopher L Corless, Kenneth R McQuaid, Harinder Garewal, Richard E Sampliner, Thomas G Morales, Ronnie Fass, Robert E Smith, Yogesh Maheshwari, David G Weiss, None, One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. The New England Journal of Medicine. ,vol. 345, pp. 555- 560 ,(2001) , 10.1056/NEJMOA010328
D.M Parkin, F.I Bray, S.S Devesa, Cancer burden in the year 2000. The global picture. European Journal of Cancer. ,vol. 37, pp. 4- 66 ,(2001) , 10.1016/S0959-8049(01)00267-2
Eva Martinez-Balibrea, Carmen Plasencia, Alba Ginés, Anna Martinez-Cardús, Eva Musulén, Rodrigo Aguilera, José Luis Manzano, Nouri Neamati, Albert Abad, A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Molecular Cancer Therapeutics. ,vol. 8, pp. 771- 778 ,(2009) , 10.1158/1535-7163.MCT-08-0882
David A. Lieberman, Cost-effectiveness model for colon cancer screening Gastroenterology. ,vol. 109, pp. 1781- 1790 ,(1995) , 10.1016/0016-5085(95)90744-0
M Naumann, B Schaum, G M Oremek, E Hanisch, W Rösch, J Mössner, W F Caspary, J Stein, [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study]. Deutsche Medizinische Wochenschrift. ,vol. 129, pp. 1806- 1807 ,(2004) , 10.1055/S-2004-829033